Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.14 USD | -0.72% | -2.72% | +15.67% |
May. 31 | Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test | MT |
May. 31 | Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test | MT |
Financials (USD)
Sales 2024 * | 832M | Sales 2025 * | 897M | Capitalization | 2B |
---|---|---|---|---|---|
Net income 2024 * | -92M | Net income 2025 * | -64M | EV / Sales 2024 * | 2.3 x |
Net cash position 2024 * | 93.93M | Net cash position 2025 * | 116M | EV / Sales 2025 * | 2.1 x |
P/E ratio 2024 * |
-23.6
x | P/E ratio 2025 * |
-31.6
x | Employees | 2,700 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.91% |
Latest transcript on Myriad Genetics, Inc.
1 day | -0.72% | ||
1 week | -2.72% | ||
Current month | -2.72% | ||
1 month | -12.32% | ||
3 months | -2.08% | ||
6 months | +19.55% | ||
Current year | +15.67% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Diaz
CEO | Chief Executive Officer | 61 | 20-08-12 |
Scott Leffler
DFI | Director of Finance/CFO | 49 | Jan. 28 |
Dale Muzzey
CTO | Chief Tech/Sci/R&D Officer | 44 | 14-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
S. Phanstiel
CHM | Chairman | 65 | 09-09-15 |
Paul Bisaro
BRD | Director/Board Member | 63 | 22-10-30 |
Dan Spiegelman
BRD | Director/Board Member | 65 | 20-05-26 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.24% | 15 M€ | -3.61% | ||
0.26% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 22.14 | -0.72% | 502,558 |
24-06-06 | 22.3 | -1.76% | 503,381 |
24-06-05 | 22.7 | +1.61% | 617,263 |
24-06-04 | 22.34 | -0.04% | 828,642 |
24-06-03 | 22.35 | -1.80% | 944,210 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.67% | 2B | |
-6.76% | 11.98B | |
-5.68% | 8B | |
+8.91% | 5.85B | |
+28.87% | 5.54B | |
-15.84% | 3.84B | |
+10.70% | 2.66B | |
-60.92% | 2.62B | |
-6.99% | 2.33B | |
-8.85% | 1.78B |
- Stock Market
- Equities
- MYGN Stock